{"product_id":"vygon-bcg-matrix","title":"Vygon S.A. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVygon S.A.'s BCG Matrix preview highlights which product lines lead the market and which tie up capital — a quick reality check for any CFO or founder. Want the full picture? Purchase the complete BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and a clear roadmap for resource allocation. Delivered in ready-to-use Word and Excel formats, it’s the strategic shortcut that saves hours of research and helps you act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeonatology catheters and IV access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh share in a fast-growing neonatal care market driven by specialized demand positions Vygon’s neonatology catheters and IV access as a star. Clinicians prioritize precision and safety, and Vygon’s product depth, KOL relationships and clinical protocols set the pace. Maintaining leadership requires ongoing training, KOL work and robust clinical evidence. Hold the line and the franchise will mature into a reliable cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePICC and midline lines for critical care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePICC and midline lines show strong ICU uptake where reliability and infection control are non-negotiable; CDC estimates a CLABSI can add up to $45,000 per case, driving demand for safer devices. Market expansion is fueled by aging populations and complex therapies, with 2024 industry reports citing ~6% CAGR for vascular access devices to 2028. Continuous investment in antimicrobial coatings, nurse education and placement support is required to defend share now to harvest later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArterial pressure monitoring sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArterial pressure monitoring sets are essential hardware in high-acuity ICUs and ORs, with the invasive blood pressure market estimated at about USD 1.1 billion in 2024 and ~5% CAGR reflecting steady procedural volume growth. Vygon can win on accuracy, ease of use, and supply reliability to capture share from disposables and OEMs. Promotion and clinical partnerships remain critical to stay on protocol lists and drive adoption. Scale now to convert this product line into a cash cow as growth normalizes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional anesthesia and epidural kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRising perioperative volumes and wider adoption of enhanced recovery after surgery protocols—ERAS programs show length-of-stay reductions of 30–50%—favor regional techniques, positioning regional anesthesia and epidural kits as a BCG Matrix star for Vygon. Vygon’s complete kits simplify OR workflow and reduce variability, but sustained rep presence and clinician education are required to keep standards. Channel feeding remains crucial as the category continues to grow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand: ERAS drives regional uptake (LOS −30–50%)\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: ready-to-use kits reduce variability in ORs\u003c\/li\u003e\n\u003cli\u003eGo-to-market: requires reps + education to maintain share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmergency and vascular access kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmergency and vascular access kits are Stars in Vygon S.A.’s BCG matrix as protocol-driven ED and prehospital care expands; turnkey kits prioritize speed and safety so teams act fast. 2024 EMS market estimates (~USD 30.2B) and rising ED throughput reinforce volume upside, making training and placement critical to remain the default. Invest to cement leadership as volumes climb and preference for ready-to-use solutions grows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eED\/prehospital demand: protocol-led growth\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: speed, safety, turnkey kits\u003c\/li\u003e\n\u003cli\u003eMust-haves: training, on-site placement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeonatal \u0026amp; vascular access lead in protocol-driven niches — protect share with KOLs, coatings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVygon’s neonatology catheters, vascular access (PICC\/midline), arterial pressure sets, regional anesthesia kits and ED\/prehospital access kits are Stars—high share in fast-growth, protocol-driven niches. 2024 benchmarks: vascular access ~6% CAGR to 2028, invasive BP ~USD 1.1B (5% CAGR), EMS ~USD 30.2B. Protect share via KOLs, training, coatings and supply reliability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 size\u003c\/th\u003e\n\u003cth\u003eCAGR to 2028\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeonatal catheters\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003eClinical outcomes\u003c\/td\u003e\n\u003ctd\u003eKOLs \u0026amp; evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVascular access\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003ctd\u003eCLABSI cost av. USD45k\u003c\/td\u003e\n\u003ctd\u003eCoatings \u0026amp; education\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArterial sets\u003c\/td\u003e\n\u003ctd\u003eUSD1.1B\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003ctd\u003eProcedural volume\u003c\/td\u003e\n\u003ctd\u003eAccuracy \u0026amp; supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional kits\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003egrowing\u003c\/td\u003e\n\u003ctd\u003eERAS LOS −30–50%\u003c\/td\u003e\n\u003ctd\u003eReps \u0026amp; training\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eED kits\u003c\/td\u003e\n\u003ctd\u003eUSD30.2B (EMS)\u003c\/td\u003e\n\u003ctd\u003egrowing\u003c\/td\u003e\n\u003ctd\u003eThroughput\u003c\/td\u003e\n\u003ctd\u003ePlacement \u0026amp; training\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG snapshot of Vygon S.A.: maps Stars, Cash Cows, Question Marks and Dogs with strategic actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for Vygon S.A., placing each business unit in a quadrant to surface pain points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeripheral IV cannulas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeripheral IV cannulas are a mature, high-volume, price-sensitive segment where Vygon holds an entrenched share; steady demand and scale deliver reliable margins through operational efficiency. Low promotional spend is needed beyond contract coverage and service levels, enabling consistent cash generation. Focus on lean manufacturing and supply-chain wins lets Vygon continually milk cash flows for reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult central venous catheter sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdult central venous catheter sets sit in Vygon S.A.’s cash cow quadrant: stable procedural baseline across hospitals worldwide with predictable utilization in 2024. Differentiation is modest so execution and availability drive share; the line generated steady cash supporting core operations in 2024 while requiring limited marketing lift. Prioritize maintaining clinical quality, locking in hospital supply frameworks and optimizing cost to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnteral feeding tubes and sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChronic and inpatient use of enteral feeding tubes and sets gives Vygon stable, predictable demand, with enteral nutrition used in roughly 30–60% of ICU patients and a large share consumed in hospitals (≈60–80% of volumes). Compliance and cross-brand compatibility sustain market share and reduce churn. Small design and material innovations typically lift gross margins by a few percentage points rather than driving volume growth. Harvest via targeted SKU rationalization and optimized logistics to cut carrying costs and improve cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfusion accessories (connectors, stopcocks, caps)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInfusion accessories (connectors, stopcocks, caps) are cash cows for Vygon S.A., delivering steady pull-through from established lines with high repeat purchase and low churn when manufacturing quality is consistent. Promotion is light; long-term hospital contracts and distributor agreements sustain volume and margins. Surplus cash from these consumables funds R\u0026amp;D and next-wave platform investments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh repeat purchase, low churn\u003c\/li\u003e\n\u003cli\u003eContract-driven sales, low promo spend\u003c\/li\u003e\n\u003cli\u003eReliable gross margins for reinvestment\u003c\/li\u003e\n\u003cli\u003eFunds next-wave platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-care infusion disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHome-care infusion disposables at Vygon S.A. show steady orders from home-care providers and pharmacies, driven by predictable monthly refill cadence and low churn. Limited need for heavy marketing keeps SG\u0026amp;A lean while margins rely on production efficiency and optimized packaging. Priority is high service levels and tight cost control to protect cash-generation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003esteady orders\u003c\/li\u003e\n\u003cli\u003emonthly refill cadence\u003c\/li\u003e\n\u003cli\u003elow marketing intensity\u003c\/li\u003e\n\u003cli\u003emargin from efficiency \u0026amp; packaging\u003c\/li\u003e\n\u003cli\u003efocus: service levels + cost control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable cash cows fund R\u0026amp;D: steady hospital demand and predictable revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVygon cash cows deliver predictable, high-frequency consumable revenue in 2024, funding R\u0026amp;D and platform bets while needing minimal promo spend. Scale and supply-chain efficiency protect margins; clinical reliability and contract presence lock in hospital demand. Enteral feeding shows ICU use ~30–60% and hospital share ~60–80% of volumes, supporting steady cash conversion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeripheral IV\u003c\/td\u003e\n\u003ctd\u003eHigh-volume, price-sensitive\u003c\/td\u003e\n\u003ctd\u003eCore cash generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCentral venous sets\u003c\/td\u003e\n\u003ctd\u003eStable utilization 2024\u003c\/td\u003e\n\u003ctd\u003eMargin support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnteral tubes\u003c\/td\u003e\n\u003ctd\u003eICU use 30–60% \/ hospital 60–80%\u003c\/td\u003e\n\u003ctd\u003ePredictable demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eVygon S.A. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Vygon S.A. BCG Matrix you'll receive after purchase. No watermarks, no demo overlays—just the fully formatted, analysis-ready report crafted for clarity and decision-making. Once bought, the same document is delivered for immediate editing, printing, or presentation. No surprises—just plug-and-play strategic insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674758201721,"sku":"vygon-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/vygon-bcg-matrix.png?v=1755794840","url":"https:\/\/portersfiveforce.com\/products\/vygon-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}